Spring bank pharmaceuticals, inc. (SBPH)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss

-27,080

-24,097

-22,087

-23,955

-23,185

-22,854

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-28,617

-21,936

-17,348

-17,366

-18,912

-18,162

-16,124

-11,564

0

0

0

Adjustments for:
Depreciation and amortization

370

357

358

373

326

288

236

168

167

158

146

137

128

118

114

111

101

88

0

0

0

Operating lease right-of-use asset amortization

267

263

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liabilities

-5,630

-8,212

-8,841

-7,150

-6,236

-4,617

-8,516

-4,072

3,566

6,795

0

0

0

-

-

-

-

-

-

-

-

Non-cash interest expense

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash investment income

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Non-cash investment expense

143

28

0

0

0

-

0

0

0

-

-

-

-

-

-

-

0

-

-

-

-

Non-cash stock-based compensation

3,212

3,367

3,539

3,440

3,090

2,776

2,490

2,287

2,069

1,911

1,906

1,774

1,636

1,438

1,447

1,502

1,314

1,125

0

0

0

Non-cash issuance of common stock and warrants connected to license agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

2,780

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

1,743

1,873

698

1,197

609

1,069

179

321

128

-260

-209

-120

-634

527

1,439

1,463

1,530

732

0

0

0

Other assets

-

-132

0

0

0

-

-

-

0

-

-

-

-

35

0

0

0

-

-

-

-

Accounts payable

6

330

1,612

37

331

180

-399

-263

-383

181

-706

184

547

-812

1,814

1,059

1,004

1,835

0

0

0

Accrued expenses and other liabilities

813

358

-1,385

938

-11

-205

1,519

1,232

1,208

732

827

217

-1,044

497

0

0

0

-

-

-

-

Operating lease liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-29,449

-29,055

-27,358

-27,049

-25,843

-25,244

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Accrued expenses and other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,037

0

0

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-15,322

-15,819

-13,577

-13,405

-11,100

-8,211

0

0

0

Proceeds from sale of marketable securities

44,963

38,770

32,799

29,705

30,203

34,869

36,546

32,552

28,150

22,314

18,395

16,881

14,133

8,684

0

0

0

-

-

-

-

Purchases of marketable securities

0

-

-

-

-

58,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

203

272

267

1,183

1,793

1,972

2,109

1,213

473

323

184

164

216

213

221

238

462

389

0

0

0

Net cash provided by investing activities

23,760

23,498

18,532

-13,478

-19,590

-25,103

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-1,061

-6,507

-2,858

-1,662

-6,739

-8,931

0

0

0

Proceeds from issuance of common stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

21,648

0

0

0

Proceeds from issuance of common stock in connection with at-the-market offering, net of issuance costs

0

-

-

-

-

3,212

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Payment of finance costs related to issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,754

0

0

0

Proceeds from exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25

0

0

0

Proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

92

0

0

0

-

-

-

-

-

-

-

-

Issuance costs paid in connection with the private investment in a public entity

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Cash provided by financing activities

0

-

-

-

-

41,172

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

19,919

0

0

0

Net increase in cash, cash equivalents and restricted cash

13,883

13,985

10,734

-2,562

-7,088

-9,175

6,082

-38,100

10,034

13,449

0

0

0

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

726

-17,839

2,777

0

0

0

Supplemental disclosures of cash flow information:
Cash paid for taxes

-

-

-

-

-

3

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest, net

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-